drugset / Trial / NCT05678881
Safety, Tolerability, and Efficacy of RLS103 in a Clinical Model of Photosensitive Epilepsy
RandomizedCrossoverDouble-blindTreatment
Summary
The purpose of this study is to evaluate RLS103 for safety and suppression of the epileptic photoparoxysmal response compared to placebo.
Timeline
- Start
- 2022-04-25
- Primary completion
- 2024-02-23
- Completion
- 2024-02-23
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cannabidiol | Other / unclassified | 4 mg | Inhaled |
| Subject | Cannabidiol | Other / unclassified | 8 mg | Inhaled |